4D pharma plc: 4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) a novel class of drug derived from the microbiome, today announces Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald s virtual panel, titled Microbiome Players with Guided Readouts in 2021, on Thursday, February 18, 2021 at 15:00 GMT (10:00 ET).
A webcast of the panel will be available via the Events section of the 4D pharma website at www.4dpharmaplc.com.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationall
4D pharma plc: 4D pharma to Participate in 5th Microbiome Movement Drug Development Summit Europe
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) a novel class of drug derived from the microbiome, today announced its participation in the Microbiome Movement Drug Development Summit Europe, including the Plenary Session, Microbiome Leaders Industry Review Panel.
Plenary Session: European Microbiome Leaders Panel Discussion on Thursday, January 28, 2021 at 8:00am GMT (3:00am ET) with Chief Scientific Officer, Dr. Alex Stevenson, Ph.D.
Clinical Trial Design and Evaluating PK/PD Session: MicroRx and Single Strain Live Biotherapeutics: Proof of Concept Clinical Data and Future Considerations on Thursday, January 28, 2021 at 11:30pm GMT (6:30am ET) with Research Director, Dr. Imke Mulder